Compare Campbell Soup Co. (CPB) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Novo Nordisk A/S — how do they compare? Campbell Soup Co. trades at $19.21 (market cap $5.78B), while Novo Nordisk A/S trades at $38.45 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 28.6× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (5.16%). Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and Novo Nordisk A/S for 116 Days on average.
| CPB | NVO | |
|---|---|---|
Market Cap | $5.78B | $165.31B |
Volume | 11,705,427 | 11,432,838 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $63.98 |
52-Week Low | $18.90 | $35.29 |
Typical Hold Time | 98 Days | 116 Days |
Enterprise Value | $12.83B | $179.56B |
Dividend Yield | 5.16% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $19.12, up 1.16% on the day, with a bearish technical outlook and mixed analyst sentiment. The company reported a Q4 2026 earnings miss but beat expectations in Q1 and Q2 2026. Recent developments include a 36% dividend cut, a $500 million cost savings program, and workforce reductions. Valuation metrics show a P/E of 14.79 and P/S of 0.6, suggesting potential undervaluation amid operational challenges.
The outlook remains cautious due to margin pressure and declining sales, though cost-cutting initiatives and brand strength in segments like Rao's offer long-term potential. Key risks include execution of turnaround plans and competitive pressures. The consensus price target is $19.73, with most analysts rating Hold.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
